Itepekimab — Drug Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

0 Recruiting

8 Completed trials

1 Sponsors

22 Countries

Phase III

Phase II

Phase III: 6 Phase II: 3

Indications tested

Chronic obstructive pulmonary disease 4 Chronic rhinosinusitis with nasal polyps 3 Bronchiectasis 1 Chronic rhinosinusitis without nasal polyps 1

Sponsors using this IMP

Sanofi-Aventis Recherche & Developpement 9

All trials

9 total

An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr… Pending

2025-522983-33-00 Phase III 15 countries Sanofi-Aventis Recherche & Developpement
A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (antiIL33 mAb) in participants with inadequately-controlled… Ended

2024-516815-26-00 Phase III 11 countries Sanofi-Aventis Recherche & Developpement
A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (antiIL33 mAb) in participants with inadequately-controlled… Ended

2024-516814-39-00 Phase III 10 countries Sanofi-Aventis Recherche & Developpement
A Proof of Concept study to assess the efficacy, safety and tolerability of itepekimab (antiIL33 mAb) in participants with chronic rhinosi… Ended

2024-515576-12-00 Phase II 7 countries Sanofi-Aventis Recherche & Developpement
A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended

2023-508085-15-00 Phase III 18 countries Sanofi-Aventis Recherche & Developpement
A Proof-of-Concept study to assess the efficacy, safety and tolerability of itepekimab (anti-IL-33 mAb) in participants with non-cystic fibr… Ended

2023-508663-70-00 Phase II 9 countries Sanofi-Aventis Recherche & Developpement
Mechanistic study of the effect of itepekimab on airway inflammation in patients with COPD Ended

2024-512007-39-00 Phase II 4 countries Sanofi-Aventis Recherche & Developpement
Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab in chronic obstructive pulmonary disease (COPD) (AER… Ended

2024-512012-21-00 Phase III 12 countries Sanofi-Aventis Recherche & Developpement
Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab in chronic obstructive pulmonary disease (COPD) (AER… Ended

2024-512013-41-00 Phase III 8 countries Sanofi-Aventis Recherche & Developpement

Showing 1–9 of 9 trials

← All drugs A–Z